OPKO Health’s amended Nicoya deal and what it means for investors

OPKO Health (OPK) recently amended its agreement with Nicoya Therapeutics, adding a 15% equity stake and revising royalty and transfer pricing as both companies work to broaden RAYALDEE access across Greater China.

OPKO’s 26.32% 1 month share price return and 21.01% 3 month share price return suggest momentum has picked up recently. However, the 5 year total shareholder return, which is down 60.33%, shows longer term holders have experienced meaningful value erosion.

If RAYALDEE’s China push has your attention, it could be a good moment to look at other healthcare names using AI, including those in our curated list of 38 healthcare AI stocks.

With OPKO shares up 26.32% over the past month but still down 60.33% over five years, the question is simple: are you looking at a recovery story on sale, or is the market already pricing in future growth?

Most Popular Narrative: 57.6% Undervalued

With OPKO Health closing at $1.44 against a narrative fair value of $3.40, the current price sits well below what this widely followed model suggests.

The sale of BioReference's oncology and related clinical testing assets to Labcorp is expected to sharpen OPKO Health's focus on its core testing business, drive significant cost savings, and support the Diagnostics segment's transition to cash flow positive and profitability in 2025, providing margin expansion and stabilizing earnings.

Curious what has to happen for $3.40 to make sense? The narrative leans on steadier revenue, higher margins, and a rich future earnings multiple. The exact mix of those drivers might surprise you.

Result: Fair Value of $3.40 (UNDERVALUED)

However, the story can change quickly if OPKO stays loss making or if key products like 4Kscore, Rayaldee or NGENLA underperform expectations and pressure cash flow.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Revenue Multiple Sends A Caution Flag

The narrative model points to a fair value of $3.40, yet OPKO trades on a P/S of 1.9x, which is higher than both the US Healthcare average at 1.2x and peer levels at 1.5x, and above a fair ratio of 0.5x that the market could move toward over time.

That gap suggests the stock already carries valuation risk if growth or profitability do not improve meaningfully. The key question is whether you think OPKO can earn its way into this richer revenue multiple or if expectations are running ahead of the fundamentals.

Next Steps

If all this leaves you slightly torn between the upside story and the valuation warnings, take advantage of the current information and stress test the thesis against the 1 important warning sign.

Looking for more investment ideas?

If OPKO has sparked new questions, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that could suit your style and risk appetite.

• Target potential upside with a curated set of screener containing 21 high quality undiscovered gems that many investors may be overlooking right now.
• Prioritise resilience by scanning 63 resilient stocks with low risk scores when you want companies with lower risk scores front and center.
• Focus on financial strength by checking solid balance sheet and fundamentals stocks screener (46 results) so you can research businesses backed by sturdier balance sheets and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.